Bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders

Abstract

Disclosed are a bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders, a method for treating and/or preventing hepatitis virus-related diseases or disorders by using the bisdiazabicyclo compound, and a use of the bisdiazabicyclo compound in the preparation of a drug for treating and/or preventing hepatitis virus-related diseases or disorders, and/or eliminating or mitigating hepatitis virus-related diseases or disorders.

What is Claimed: 
     
         1 - 35 . (canceled) 
     
     
         36 . A method of using a compound for treatment and/or prevention of a disease or disorder associated with a hepatitis virus, wherein the method comprises administering a therapeutically and/or prophylactically effective amount of the compound to a patient having the disease or disorder associated with a hepatitis virus, and the compound is a bisdiazabicyclo compound or a pharmaceutically acceptable salt thereof. 
     
     
         37 . The method according to claim,  36 , wherein the compound has the following structure: 
       
         
           
           
               
               
           
         
         Wherein 
         X is selected from: 
       
       
         
           
           
               
               
           
         
       
       and —SO 2 —;
 Y is selected from —O—, —S—, and is absent when X is —SO 2 —; 
 R is selected from 
 
       
         
           
           
               
               
           
         
       
       and
 R 1  is selected from 
 
       
         
           
           
               
               
           
         
       
       wherein Z is O, S or NH;
 wherein the ring A is a C 4-8  aliphatic ring; and B is phenyl, naphthyl, pyridyl, pyridazinyl, pyrazinyl or pyrimidinyl, and is optionally substituted by 1 to 4 groups independently selected from halogen, —OCF 3 , —NO 2 , —CN, —NC, —OH, amino, C 1-10  alkyl, C 1-10  alkyloxy, and C 1-10  alkylamino 
 
     
     
         38 . The method according to  claim 37 , wherein R is 
       
         
           
           
               
               
           
         
         wherein p is 0 to 4. 
       
     
     
         39 . The method according to  claim 37 , wherein R is 
       
         
           
           
               
               
           
         
         wherein phenyl is optionally substituted by 1 to 4 groups independently selected from halogen, 
         —OCF 3 , —NO 2 , —CN, —NC, —OH, amino, C 1-10  alkyl, C 1-10  alkylamino. 
       
     
     
         40 . The method according to  claim 39 , wherein R is 
       
         
           
           
               
               
           
         
       
     
     
         41 . The method according to  claim 37 , wherein R 1  i 
       
         
           
           
               
               
           
         
       
       wherein phenyl is optionally substituted by 1 to 4 groups independently selected from halogen, —OCF 3 , —NO 2 , —NC, —OH, amino, C 1-10  alkyl, C 1-10  alkyloxy and C 1-10  alkylamino. 
     
     
         42 . The method according to  claim 37 , wherein R 1  is 
       
         
           
           
               
               
           
         
       
       wherein phenyl is optionally substituted by 1 to 4 groups independently selected from halogen, —OCF 3 , —NO 2 , —CN, —NC, —OH, amino, C 1-10  alkyl C 1-10 alkyloxy and C 1-10  alkylamino. 
     
     
         43 . The method according to  claim 41 , wherein R 1  is 
       
         
           
           
               
               
           
         
       
     
     
         44 . The method according to  claim 37 , wherein X is 
       
         
           
           
               
               
           
         
       
       and Y is —NC—. 
     
     
         45 . The method according to  claim 37 , wherein X is 
       
         
           
           
               
               
           
         
       
       and Y is —NH—. 
     
     
         46 . The method according to  claim 37 , wherein X is 
       
         
           
           
               
               
           
         
       
       and Y is —O—. 
     
     
         47 . The method according to  claim 37 , wherein the compound is selected from 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         48 . The method according to  claim 37 , wherein the compound is selected from 
       
         
           
           
               
               
           
         
       
     
     
         49 . The method according to  claim 37 , wherein the compound is selected from 
       
         
           
           
               
               
           
         
       
     
     
         50 . The method according to  claim 36 , wherein the disease or disorder associated with hepatitis virus is a disease or disorder associated with hepatitis A virus, hepatitis B virus or hepatitis C virus. 
     
     
         51 . The method according to  claim 36 , wherein the disease or disorder associated with hepatitis A, hepatitis B, hepatitis C, and liver cirrhosis. 
     
     
         52 . The method according to  claim 36 , wherein the compound treats and/or prevents the disease or disorder associated with hepatitis virus by modulating an immune response. 
     
     
         53 . The method according to  claim 36 , wherein the method comprises using the compound in combination with a drug known to treat HBV.